Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.

The Journal of thoracic and cardiovascular surgery - 1 Nov 2014

Kandioler Daniela, Schoppmann Sebastian F, Zwrtek Ronald, Kappel Sonja, Wolf Brigitte, Mittlböck Martina, Kührer Irene, Hejna Michael, Pluschnig Ursula, Ba-Ssalamah Ahmed, Wrba Fritz, Zacherl Johannes

Abstract excerpt

BACKGROUND: Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer. Both drugs are believed to act via a p53-dependent apoptosis pathway. The TP53 gene is frequently mutated in esophageal cancer. OBJECTIVE: To test the value of TP53 as a biomarker prognosing outcome in patients with neoadjuvantly treated esophageal cancer. PATIENTS AND METHODS: The investigation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Austria
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Esophageal Neoplasms

Share to Fluorouracil

Share to Kaplan-Meier Estimate

Share to Neoadjuvant Therapy

Share to Proportional Hazards Models

Source

Identifiers

PMID: 25135238
DOI: 10.1016/j.jtcvs.2014.06.079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.PMID 25135238Read ↗

Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.Semantic proximity Read ↗

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

[Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study].Semantic proximity Read ↗

Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.Semantic proximity Read ↗

The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis.Semantic proximity Read ↗

Alterations of the TP53 gene in gastric and esophageal carcinogenesis.Semantic proximity Read ↗

Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.Semantic proximity Read ↗

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Semantic proximity Read ↗

p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma.Semantic proximity Read ↗

The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability.Semantic proximity Read ↗

ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.Semantic proximity Read ↗

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.